The differential diagnosis of systemic sclerosis

Current Opinion in Rheumatology

Volumn 25, Issue 6, 2013, Pages 692-699

  Tyndall, Alan ^a   Fistarol, Susanna ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Differential diagnosis; Fasciitis; Morphea; Pseudoscleroderma; Scleroderma; Scleromyxoedema; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CYCLOSPORIN; DNA TOPOISOMERASE; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 5; METHOTREXATE; MUCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARAPROTEIN; RAPAMYCIN; RNA POLYMERASE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CENTROMERE; DIFFERENTIAL DIAGNOSIS; EOSINOPHIL; EOSINOPHILIC FASCIITIS; HUMAN; MACROPHAGE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PUVA; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SCLEROEDEMA ADULTORUM; SCLEROMYXEDEMA; SKIN BIOPSY; SKINFOLD; SYSTEMIC SCLEROSIS;

CONNECTIVE TISSUE DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; NEPHROGENIC FIBROSING DERMOPATHY; SCLEREDEMA ADULTORUM; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SCLEROMYXEDEMA; SYNOVITIS;

EID: 84885297509     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/01.bor.0000434599.51526.47     Document Type: Review

References (23)

1. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23:581-590
2. Johnson SR, Fransen J, Khanna D, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 2012; 64:358-367
3. .Kitko CL, White ES, Baird K. Fibrotic and sclerotic manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012; 18:S46-S52. An excellent current description of GvHD pathophysiology
4. .Barragan-Martinez C, Speck-Hernandez CA, Montoya-Ortiz G, et al. Organic solvents as risk factor for autoimmune diseases: A systematic review and meta-Analysis. PLoS One 2012; 7:e51506
5. Shulman LE Diffuse fasciitis with eosinophilia: A new syndrome? Trans Assoc Am Physicians 1975; 88:70-86
6. Antic M, Lautenschlager S, Itin PH. Eosinophilic fasciitis 30 years after-what do we really know? Report of 11 patients and review of the literature. Dermatology 2006; 213:93-101
7. Imai T, Sitoh M, Matzumoto H. Eosinophilic fasciitis: MRI evaluation. Neurology 2003; 61:416
8. Garcia VP, de Quiros JF, Caminal L. Autoimmune hemolytic anemia associated with eosinophilic fasciitis. J Rheumatol 1998; 25:1864-1865
9. Junca J, Cuxart A, Tural C, et al. Eosinophilic fasciitis and non-Hodgkin lymphoma. Eur J Haematol 1994; 52:304-306
10. Khanna D, Verity A, Grossman JM. Eosinophilic fasciitis with multiple myeloma: A new haematological association. Ann Rheum Dis 2002; 61:1111-1112
11. Endo Y, Tamura A, Matsushima Y, et al. Eosinophilic fasciitis: Report of two cases and a systematic review of the literature dealing with clinical variables that predict outcome. Clin Rheumatol 2007; 26:1445-1451
12. Montgomery H, Underwood LJ. Lichen myxedematosus; differentiation from cutaneous myxedemas or mucoid states. J Invest Dermatol 1953; 20:213-236
13. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44:273-281
14. Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 1978; 199:545-547
15. Lacy MQ, Hogan WJ, Gertz MA, et al. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol 2005; 141:1277-1282
16. Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: A case report and review of the literature. Semin Arthritis Rheum 2006; 35:355-359
17. Ranganathan P. Infliximab-induced scleredema in a patient with rheumatoid arthritis. J Clin Rheumatol 2005; 11:319-322
18. Wright RA, Bernie H. Scleredema adultorum of Buschke with upper esophageal involvement. Am J Gastroenterol 1982; 77:9-11
19. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356:1000-1001
20. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: Predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007; 56:3433-3441
21. Nazarian RM, Mandal RV, Kagan A, et al. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: A diagnostic aid. J Am Acad Dermatol 2011; 64:741-747
22. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: Suspect identified, motive unclear. Am J Dermatopathol 2003; 25:358
23. Bernstein EJ, Schmidt-Lauber C, Kay J. Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol 2012; 26:489-503